ArticleFrontiers in veterinary science2026
Genetic recombination and pathogenicity assessment of porcine reproductive and respiratory syndrome virus 2 strains in China.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine reproductive and respiratory syndrome virus type 2 (PRRSV-2) has been endemic in China for more than three decades; however, comprehensive epidemiological investigations under field conditions remain limited in recent years. To address this gap, a total of 21,413 clinical samples were collected from 6,974 pig farms across 31 provinces in China between 2023 and 2024 to investigate the epidemiological dynamics of PRRSV-2. Phylogenetic analysis of 1,528 ORF5 sequences identified five major circulating lineages: lineage 1.8 (NADC30-like), lineage 1.5 (NADC34-like), lineage 3.5 (QYYZ-like), lineage 5.1 (VR2332-like), and lineage 8.7 (HP-PRRSV). Among these, lineage 1.8 predominated in both 2023 (47.29%) and 2024 (49.08%). To further characterize the genomic features and pathogenicity of the dominant clinical strains, five recombinant lineage 1.8 PRRSV isolates harboring a characteristic discontinuous 131-amino-acid deletion in nsp2 were successfully isolated. Pathogenicity assessments in piglets revealed distinct differences in virulence among three representative isolates, as reflected by elevated rectal temperatures, reduced average daily weight gain, and high levels of viremia and viral loads in serum, nasal swabs, spleen, lungs, and lymph nodes. Notably, strains with a JXA1-like major parental backbone and an NADC30-like minor parental contribution exhibited higher pathogenicity than those with an NADC30-like major parent and a WUH4-like minor parent. Collectively, this study demonstrates that PRRSV-2 circulation in China is characterized by pronounced seasonality, extensive genetic recombination, and the dominance of genetically diverse lineage 1.8 strains, including recombinants, providing critical insights for targeted surveillance and effective control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.